Companies › BioNTech Cell & Gene Therapies
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CLDN6 CAR-T CAR-T cell therapy targeting CLDN6 | CLDN6 | Phase 1 | Solid Tumor | Aug 2028 |
| CLDN6 uRNA-LPX/CLDN6 modRNA-LPX RNA-based vaccine targeting CLDN6 | CLDN6 | Phase 1 | Solid Tumor | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04503278 | CLDN6 CAR-T | Phase 1 | Solid Tumor | Oncology | Aug 2028 |
| NCT04503278 | CLDN6 uRNA-LPX/CLDN6 modRNA-LPX | Phase 1 | Solid Tumor | Oncology | Aug 2028 |
Context Therapeutics BeOne Medicines NovaRock Biotherapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.